XIENCE(TM) V Drug Eluting Stent From Abbott Reduces Major Adverse Cardiac Events In Small Vessel Patients Out To One Year

Data presented from an independent pooled subset analysis of Abbott’s SPIRIT II and SPIRIT III clinical trials demonstrated a clinically significant 51 percent reduction in major adverse cardiac events (MACE) with the XIENCE? V Everolimus Eluting Coronary Stent System compared to the TAXUS® paclitaxel-eluting coronary stent system in patients with small vessels out to one year. The data were presented during an Abbott-sponsored symposium at EuroPCR 2008.

More: continued here

Filed under: Cardiovascular on May 22nd, 2008